Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336188 · ClinicalTrials.gov registry record · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
A Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging, sponsored by University of Arkansas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
- 1
- Study location
NCT05336188 is a Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 255 participants, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05336188, a Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to standard app-based self-monitoring of drug use and personalized feedback, project innovation is enhanced by the proposed use of location-tracking technology for targeted, personalized intervention when participants enter self-identified areas of high risk for relapse. Furthermore, the proposed sub-study would use longitudinal functional neuroimaging to elucidate the brain-cognition relationships underlying individual differences in treatment outcomes, offering broad significance for understanding and enhancing the efficacy of this and other app-based interventions.
Conditions Studied
Interventions
- DEVICE Smartphone
Study Locations (1)
Arkansas
- Brain Imaging Research Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336188
The ClinicalTrials.gov registry entry for NCT05336188 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (25% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Smartphone is the first listed.
NCT05336188 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT05336188 about?
NCT05336188 is a clinical study titled "Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder". The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to standard app-based self...
What is the current status of trial NCT05336188?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2023-05-16. Estimated completion is 2028-09-30.
What conditions does trial NCT05336188 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Magnetic Resonance Imaging, Craving, Opiate Substitution Treatment, Mobile Applications.
What interventions are being tested in trial NCT05336188?
The interventions under investigation include: Smartphone (DEVICE).
Who is sponsoring clinical trial NCT05336188?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336188 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.